RxDoctor Payments DataLook up a doctor →

Ricky Ganim, MD

Interventional Cardiology · Humble, TXNPI 1295843019

Payments from drug & device makers

$960,081in general payments, 2019–2025

Across 968 payments — averaging $991.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$461K
  • Bard Peripheral Vascular, Inc.$143K
  • GE HealthCare$125K
  • Medtronic$103K
  • Janssen Research & Development, LLC$62K
  • AstraZeneca$18K
  • plus $47K from 54 others

What the payments were for

  • Royalty or licence$102,08471%
  • Consulting fees$3,7503%
  • Travel & lodging$2,1992%
  • Food & beverage$22,09515%
  • Education$220%
  • Other$13,4869%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen47$461,127
Bard Peripheral Vascular, Inc.35$143,311
GE HealthCare12$125,494
Medtronic(2 entities)17$102,974
Janssen Research & Development, LLC15$61,884
AstraZeneca23$17,974
Angiodynamics, Inc.69$14,499
Bayer3$8,596
Boston Scientific114$8,431
Abbott43$2,780
Novartis144$1,988
Corindus Inc.9$1,396
Shockwave Medical, Inc49$1,015
E.r. Squibb & Sons, L.L.C.40$676
Johnson & Johnson45$609
Merck31$567
Cardiovascular Systems Inc.18$566
Pfizer26$523
Cvrx, Inc.7$444
Amarin Pharma, Inc.23$414
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)27$399
Esperion Therapeutics, Inc.24$360
Impulse Dynamics (USA) Inc.14$333
Kestra Medical Technology Services, Inc.3$306
Novo Nordisk15$278
Heartflow, Inc.5$274
Tactile Systems Technology Inc18$246
Biotronik Inc.7$230
Philips North America LLC4$194
Penumbra, Inc.1$180
Endologix LLC2$169
Cardiva Medical, Inc.5$149
Boehringer Ingelheim8$139
Sanofi-aventis U.S. LLC8$128
Chiesi USA, Inc.6$110
Canon Medical Systems USA, Inc.3$99
Cardiofocus, Inc.1$98
Kowa Pharmaceuticals America, Inc.6$95
Mindray DS USA, Inc.1$93
Atricure, Inc.2$84
Bolton Medical Inc1$66
Regeneron2$65
Actelion Pharmaceuticals US, Inc.3$57
Regeneron Healthcare Solutions, Inc.3$51
Cook Medical LLC2$42
Teleflex LLC2$39
Cordis US CORP.2$35
Siemens Medical Solutions USA, Inc.2$34
Abiomed1$33
Biom'up France SAS2$32
Terumo Medical Corporation1$32
ZOLL Circulation Inc1$28
Veryan Medical Incorporated1$28
Biohaven Pharmaceutical Holding Company Ltd.1$27
Bridgebio Pharma, Inc.1$27
Resmed Corp1$25
Alnylam Pharmaceuticals Inc.1$24
Paratek Pharmaceuticals, Inc.1$24
Astellas Pharma US Inc1$23
Xeris Pharmaceuticals, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$960,081 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$336,982
Medicare patients
638
Services billed
3,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$165,205
EntrestoSacubitril/Valsartan94$118,122
XareltoRivaroxaban95$107,514
Repatha SureclickEvolocumab78$80,427
BrilintaTicagrelor55$52,406
Repatha SyringeEvolocumab31$33,631
Praluent PenAlirocumab32$33,356
FarxigaDapagliflozin Propanediol21$29,690
JardianceEmpagliflozin16$12,360
Rosuvastatin Calcium441$6,004
ClopidogrelClopidogrel Bisulfate562$5,663
Metoprolol Succinate384$5,348
Ezetimibe209$5,141
Icosapent Ethyl15$3,927
Atorvastatin Calcium423$3,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$523$165,205151 claims
NovartisEntresto$1,988$118,12294 claims
Johnson & JohnsonXarelto$609$107,51495 claims
AstraZenecaBrilinta, Farxiga$17,974$82,09676 claims
Boehringer IngelheimJardiance$139$12,36016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →